2M.D. Asistant, Istanbul University, Istanbul Faculty of Medicine, Department of Ophthalmology, İstanbul /TURKEY
3M.D. Professor, Istanbul University, Istanbul Faculty of Medicine, Department of Ophthalmology, İstanbul /TURKEY Purpose: To evaluate the effect on functional and anatomical success of intravitreal ranibizumab injections on the classic type of choroidal neovascularization secondary to age-related macular degeneration (AMD).
Materials and Methods: 70 eyes of 64 patients with classic type subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) were included in the study. In accordance with the Pronto Protocol three-dose injections of ranibizumab and if necessary additional therapy were administered. The best corrected visual acuity, fundus findings and optical coherence tomography (OCT) were evaluated retrospectively.
Results: The mean age was 74.1±7.5 (55-88) years with 34 female and 30 male patients. Main best corrected visual acuity (BCVA) was 0.27±0.20 (0.1 to 0.6), and retinal thickness (microns) was 444.10±151.58 um (312-589 um) before treatment. Patients were followed up for 24.44±9.94 (12-48) months. The total average ranibizumab dose was 9.3 in the routine treatment of patients with 3 injected doses of ranibizumab. The difference in retinal thickness and the reduction in the value of the thickest macular location after the treatment was statistically significant. (p<0.01). The amount of hemorrhage and exudation showed no significant difference before and after injection.
Conclusion: Patients with neovascular membranes secondary to AMD who were followed by OCT-guided intravitreal ranibizumab therapy showed reduction in the retinal thickness and improved visual acuity.
Keywords : Ranibizumab,AMD, CNVM